Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis
- 1.6k Downloads
Few studies have evaluated the contribution of individual symptoms and impairments to the burden of multiple sclerosis (MS). This article reviews the contribution of walking impairment, fatigue, spasticity, depression, and pain, to quality of life (QOL) of the patient and economic burden of MS.
Studies for inclusion were chosen from the literature that reported on QOL and costs in patients with MS, identified through PubMed searches (main search terms: “multiple sclerosis” combined with “quality of life,” “costs,” or “burden”). Articles were selected based on whether the analyses included evaluation of symptoms and impairments as contributory factors to QOL or costs.
Impaired mobility was ranked to be of high concern, and was suggested to be an important contributory factor to QOL, having a greater impact on physical components than mental components. Fatigue was associated with QOL, with effects on both physical and mental components of QOL, independent of disability level. Depression was inversely associated with QOL. Spasticity may affect physical components of QOL, and daily activities may be impacted in as many as 44% of patients with MS. Pain, occurring in up to 86% of patients with MS, impacts daily function and QOL across the range of physical and mental domains. The contribution of these impairments and symptoms to the economic burden has been less well characterized, although the importance of mobility to employment and productivity has been suggested by several studies.
Evidence suggests that impaired mobility and symptoms such as fatigue, pain, depression, and spasticity are important contributory factors to the observed reduction in QOL, and in some cases, increased costs, associated with MS. There is a need for greater recognition of the presence and effects of these disabilities, and effective targeted treatment options for specific impairments, potentially resulting in improved QOL and reduced indirect costs.
Keywordsburden costs depression fatigue impairment mobility multiple sclerosis pain quality of life spasticity walking
- 1.National Multiple Sclerosis Society web site. About MS. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/index.aspx. Accessed April 3, 2009.
- 6.Henze T, Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56:78–105.CrossRefPubMedGoogle Scholar
- 22.Kurtzke JF, Wallin MT. Epidemiology. In: Burks JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos Medical Publishing, Inc; 2000:49–71.Google Scholar
- 35.World Health Organization (WHO). International Classification of Functioning, Disability and Health (ICF). Available at: http://www.who.int/classifications/icfbrowser/. Accessed April 3, 2009.
- 38.Datamonitor Healthcare Reports. Treatment algorithms 1999: segmenting the multiple sclerosis patient population. London, UK: Datamonitor Healthcare Reports; 1999.Google Scholar
- 45.The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of life. Can J Neurol Sci. 1998;25:31–38.Google Scholar
- 68.Edgley K, Sullivan M, Dehoux E. A survey of multiple sclerosis: II. Determinants of employment status. Can J Rehabil. 1991;4:127–132.Google Scholar